Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

• Status: Terminated
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: Leudosite
• Treatments: Alemtuzumab

Criteria

Inclusion Criteria:

1. 15-65 years old

2. B or T-cell lymphoid disease, not eligible for non-myeloablative transplantation.

3. Patients in relapse after failing conventional chemotherapy.

4. Patients with HLA-identical or one-antigen mismatched sibling, or a matched unrelated donor.

5. Performance status Exclusion Criteria:

1. Past history of anaphylaxis following exposure to rat or mouse derived CDR-grafted humanized monoclonal antibodies.

2. Less than 4 weeks since prior chemotherapy.

3. Pregnancy or lactation.

4. HIV or HTLV-I positivity.

5. Serum creatinine >1.6 mg/dl or serum bilirubin >0.2 mg/dl unless due to tumor, SGPT >/= 2 x NI

6. PFT-DCLO<50%, cardiac EF <50% of predicted levels.